{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:01:16Z","timestamp":1793289676255,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.jtauto.2023.100188","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T04:07:34Z","timestamp":1672891654000},"page":"100188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales"],"prefix":"10.1016","volume":"6","author":[{"given":"Francesca","family":"Colapietro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Eric","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-7902","authenticated-orcid":false,"given":"Ana","family":"Lleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtauto.2023.100188_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"Association for the study of the liver. Electronic address, L. European association for the study of the. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jtauto.2023.100188_bib2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtauto.2023.100188_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtauto.2023.100188_bib4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jtauto.2023.100188_bib5","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtauto.2023.100188_bib6","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/jm049904b","article-title":"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid","volume":"47","author":"Pellicciari","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jtauto.2023.100188_bib7","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jtauto.2023.100188_bib8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2023.100188_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jtauto.2023.100188_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","author":"Issemann","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.jtauto.2023.100188_bib11","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jtauto.2023.100188_bib12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jtauto.2023.100188_bib13","doi-asserted-by":"crossref","first-page":"3J","DOI":"10.1016\/S0002-9149(03)00610-6","article-title":"The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease","volume":"92","author":"Hsueh","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jtauto.2023.100188_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.24148","article-title":"Nuclear receptors in liver disease","volume":"53","author":"Wagner","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jtauto.2023.100188_bib15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbrc.2004.09.110","article-title":"PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats","volume":"324","author":"Toyama","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jtauto.2023.100188_bib16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","article-title":"PPARalpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats","volume":"56","author":"Rodriguez-Vilarrupla","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jtauto.2023.100188_bib17","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/hq1101.098228","article-title":"Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression","volume":"21","author":"Post","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jtauto.2023.100188_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jtauto.2023.100188_bib19","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jtauto.2023.100188_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1042\/bj20020981","article-title":"Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice","volume":"369","author":"Kok","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.jtauto.2023.100188_bib21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1194\/jlr.M400132-JLR200","article-title":"Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4","volume":"45","author":"Shoda","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jtauto.2023.100188_bib22","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1194\/jlr.M027433","article-title":"Metabolomics reveals an essential role for peroxisome proliferator-activated receptor alpha in bile acid homeostasis","volume":"53","author":"Li","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jtauto.2023.100188_bib23","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/hep.20705","article-title":"Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis","volume":"41","author":"Harada","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jtauto.2023.100188_bib24","article-title":"PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice","volume":"21","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jtauto.2023.100188_bib25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1126\/science.1087344","article-title":"Transcriptional repression of atherogenic inflammation: modulation by PPARdelta","volume":"302","author":"Lee","year":"2003","journal-title":"Science"},{"issue":"Pt 3","key":"10.1016\/j.jtauto.2023.100188_bib26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1042\/bj3140781","article-title":"Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse","volume":"314","author":"Chianale","year":"1996","journal-title":"Biochem. J."},{"key":"10.1016\/j.jtauto.2023.100188_bib27","first-page":"669","article-title":"Effect of clofibrate on plasma levels of alkaline phosphatase","volume":"297","author":"Zumoff","year":"1977","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2023.100188_bib28","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtauto.2023.100188_bib29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.jtauto.2023.100188_bib30","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American association for the study of liver diseases","author":"Lindor","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jtauto.2023.100188_bib31","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jtauto.2023.100188_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhepr.2019.05.005","article-title":"New treatments\/targets for primary biliary cholangitis","volume":"1","author":"Corpechot","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jtauto.2023.100188_bib33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1386-6346(99)00033-9","article-title":"Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis","volume":"16","author":"Iwasaki","year":"1999","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.jtauto.2023.100188_bib34","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2023.100188_bib35","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.14309\/ajg.0000000000001343","article-title":"Obeticholic acid and fibrates in primary biliary cholangitis: comparative effects in a multicentric observational study","volume":"116","author":"Reig","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jtauto.2023.100188_bib36","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/hep.31613","article-title":"Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate","volume":"73","author":"Smets","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jtauto.2023.100188_bib37","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jtauto.2023.100188_bib38","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jtauto.2023.100188_bib39","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","article-title":"Fenofibrate for patients with asymptomatic primary biliary cirrhosis","volume":"10","author":"Dohmen","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jtauto.2023.100188_bib40","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis","volume":"97","author":"Ohira","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jtauto.2023.100188_bib41","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jtauto.2023.100188_bib42","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clinre.2015.02.011","article-title":"Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: a meta-analysis","volume":"39","author":"Grigorian","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jtauto.2023.100188_bib43","first-page":"2757","article-title":"Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jtauto.2023.100188_bib44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jtauto.2023.100188_bib45","article-title":"UK-wide multicenter evaluation of second-line therapies in primary biliary cholangitis","author":"Abbas","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jtauto.2023.100188_bib46","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jtauto.2023.100188_bib47","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.jtauto.2023.100188_bib48","first-page":"5","article-title":"Safety and efficacy of seladelpar in patients with primary biliary cholangitis-A phase 3, international, randomized, placebo-controlled study","volume":"17","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.jtauto.2023.100188_bib49","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtauto.2023.100188_bib50","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jtauto.2023.100188_bib51","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jtauto.2023.100188_bib52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/dia.2013.0253","volume":"16","author":"Jani","year":"2014","journal-title":"Diabetes Technol. Therapeut."},{"issue":"1","key":"10.1016\/j.jtauto.2023.100188_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jtauto.2023.100188_bib54","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000327","article-title":"A multicenter, open-label, single-arm study to evaluate the efficacy and safety of saroglitazar in patients with primary biliary cholangitis","volume":"12","author":"Vuppalanchi","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.jtauto.2023.100188_bib55","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/bjd.17933","article-title":"Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy","volume":"181","author":"Hussain","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jtauto.2023.100188_bib56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jtauto.2023.100188_bib57","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtauto.2023.100188_bib58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0304-3959(93)90228-H","article-title":"The sensory response to capsaicin during repeated topical exposures: differential effects on sensations of itching and pungency","volume":"53","author":"Green","year":"1993","journal-title":"Pain"},{"key":"10.1016\/j.jtauto.2023.100188_bib59","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","article-title":"Lysophosphatidic acid is a potential mediator of cholestatic pruritus","volume":"139","author":"Kremer","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtauto.2023.100188_bib60","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.25748","article-title":"Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions","volume":"56","author":"Kremer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jtauto.2023.100188_bib61","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1016\/S0168-8278(20)31411-2","article-title":"Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study","volume":"73","author":"Levy","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jtauto.2023.100188_bib62","article-title":"Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis","author":"Kremer","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.jtauto.2023.100188_bib63","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"Open Cardiovasc. Med. J."},{"key":"10.1016\/j.jtauto.2023.100188_bib64","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1751-2980.2012.00574.x","article-title":"Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy","volume":"13","author":"Han","year":"2012","journal-title":"J Dig Dis"}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909023000011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909023000011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:35:40Z","timestamp":1762904140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909023000011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":64,"alternative-id":["S2589909023000011"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2023.100188","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2023.100188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100188"}}